Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple
A phase 1/2 trial of Belantamab mafodotin, Nirogacestat, Dostarlimab in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.
Overview
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) is a phase 1/2 interventional study registered as NCT04126200 by GlaxoSmithKline, with 208 participants enrolled, started 2019-10-07 and due to reach its primary completion in 2025-04-17. Interventions recorded: Belantamab mafodotin, GSK3174998, Feladilimab, Nirogacestat, Dostarlimab. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
Shares Nirogacestat, Belantamab mafodotin, GSK, Dexamethasone.
- TrialSub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
Shares Feladilimab, Belantamab mafodotin, GSK, Multiple myeloma.
- TrialSub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi
Shares Nirogacestat, Belantamab mafodotin, GSK, Dexamethasone.
- TrialSub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
Shares Isatuximab, Belantamab mafodotin, GSK, Multiple myeloma.
- TrialA Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas
Shares Belantamab mafodotin, GSK, Dexamethasone, Lenalidomide.
- TrialSub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
Shares Nirogacestat, Belantamab mafodotin, GSK, Multiple myeloma.
- TrialIsatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Shares Isatuximab, Dexamethasone, Lenalidomide, Multiple myeloma.
- TrialA Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme
Shares Belantamab mafodotin, GSK, Dexamethasone, Multiple myeloma.